Synexa Life Sciences is pleased to announce its collaboration with Waters Corporation as one of the first bioanalytical laboratories to trial the new Xevo TQ Absolute XR Mass Spectrometer.
This early partnership, conducted at our Manchester site, has provided valuable insights into the instrument’s performance across a broad range of sample types and analytical challenges. The TQ Absolute demonstrated notable robustness and reproducibility, particularly in handling complex assays such as metal chelators and oligonucleotides, as well as supporting high-throughput workflows. These capabilities align with Synexa’s commitment to delivering reliable, validated bioanalytical data that meet stringent regulatory standards.
Sally Hannam, our Scientific Director, along with the rest of our team worked closely with Waters to evaluate both the hardware and software components of the system. The Waters Connect software, in particular, was found to enhance data processing efficiency and support regulatory compliance, further streamlining our bioanalytical workflows.
This collaboration reflects Synexa Life Sciences’ ongoing dedication to innovation and scientific excellence in contract research. By engaging early with new technologies, we ensure that our clients benefit from cutting-edge tools that accelerate drug development and improve clinical trial support.
For further information about our bioanalytical services or to discuss how we can support your projects, please contact us.
